Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (16887)	12/12/1998 11:15:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

Dave, I stand corrected on the prostectomy article. Vivus did indeed mention that the information came from the Journal of Urology. The part that I don't understand is that Vivus in their press release quotes a Dr Ajay Nehra who is an Assistant Professor of Urology at the Mayo Clinic. However, Nehra's name is not on the abstract. Am I missing something here?

To: VLAD who wrote (16887)	12/13/1998 4:19:00 PM
From: DaiS	Read Replies (1) \| Respond to of 23519

Vlad, Nehra is active in ED research, more on basic biochem, physiol than clinical and as you know works at Mayo clinic. Had 11 abstracts at Amsterdam conference, one involving nerve sparing. Said in Times today than Astra employees shitting themselves becasue of Zeneca axeman nicknamed "black dog". I hope to get some info from Zeneca. I can't see much point despatching letters until we see what Vivus have to say next week. Other than Japan what countries are left that are not given to Astra or Janssen? Because of self injection ban in Japan, IC users take advantage of what is known as the "rush home" technique (from Amsterdam abstracts) DaiS